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Background: Rash, liver dysfunction, and diarrhea are known major adverse events associated with erlotinib and
gefitinib. However, clinical trials with gefitinib have reported different proportions of adverse events compared to
trials with erlotinib. In an in vitro study, cytochrome P450 (CYP) 2D6 was shown to be involved in the metabolism
of gefitinib but not erlotinib. It has been hypothesized that CYP2D6 phenotypes may be implicated in different
adverse events associated with gefitinib and erlotinib therapies.
Methods: The frequency of each adverse event was evaluated during the period in which the patients received
gefitinib or erlotinib therapy. CYP2D6 phenotypes were determined by analysis of CYP2D6 genotypes using
real-time polymerase chain reaction techniques, which can detect single-nucleotide polymorphisms. The CYP2D6
phenotypes were categorized into 2 groups according to functional or reduced metabolic levels. In addition, we
evaluated the odds ratio (OR) of the adverse events associated with each factor, including CYP2D6 activities and
treatment types.
Results: A total of 232 patients received gefitinib therapy, and 86 received erlotinib therapy. Reduced function of
CYP2D6 was associated with an increased risk of rash of grade 2 or more (OR, 0.44; 95% confidence interval [CI],
0.21–0.94; *p = 0.03), but not diarrhea ≥ grade 2 (OR, 0.49; 95% CI, 0.17–1.51; *p = 0.20) or liver dysfunction ≥ grade
2 (OR, 1.08; 95% CI, 0.52–2.34; *p = 0.84) in the gefitinib cohort. No associations were observed between any
adverse events in the erlotinib cohort and CYP2D6 phenotypes (rash: OR, 1.77; 95% CI, 0.54–6.41; *p = 0.35/diarrhea:
OR, 1.08; 95% CI, 0.21–7.43; *p = 0.93/liver dysfunction: OR, 0.93; 95% CI, 0.20–5.07; *p = 0.93).
Conclusions: The frequency of rash was significantly higher in patients with reduced CYP2D6 activity who treated
with gefitinib compared to patients with functional CYP2D6. CYP2D6 phenotypes are a risk factor for the
development of rash in response to gefitinib therapy.
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Compared to cytotoxic agents, gefitinib and erlotinib are
orally available epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKI) that prolong survival,
have few hematological adverse events, and improve the
quality of life in non-small cell lung cancer (NSCLC)
patients with EGFR-active gene mutations [1-6]. The* Correspondence: kimutats@med.osaka-cu.ac.jp
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reproduction in any medium, provided the ormajor adverse events that occur with gefitinib and erloti-
nib therapy are rash, liver dysfunction and diarrhea
[1-5,7-10]. We are always faced with a decision to select
between these drugs in clinical practice for patients with
EGFR-active mutations. In general, erlotinib is associated
with higher toxicity and lower tolerability than gefitinib
because the dose of erlotinib used is nearly equal to the
maximum tolerated dose, whereas the dose of gefitinib
used is close to the minimum active dose [11,12].
Recent in vitro studies have reported different metabolic
profiles of gefitinib and erlotinib for human cytochromeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CYP1A1 metabolize both erlotinib and gefitinib. However,
CYP2D6 is involved in the metabolism of gefitinib but not
erlotinib. It has been hypothesized that gefitinib therapy
results in different adverse events compared to erlotinib
therapy due to the CYP2D6 phenotype. To test this, we
evaluated the adverse events of treatment with gefitinib
and erlotinib. CYP2D6 phenotypes were determined from
the CYP2D6 genotypes using real-time polymerase chain
reaction (PCR) techniques, which are able to detect
single-nucleotide polymorphisms (SNPs).
Methods
Study subjects and data collection
Patients with advanced NSCLC who were treated with ei-
ther gefitinib or erlotinib were retrospectively identified
by analysis of patient information for subjects prospect-
ively enrolled in the Medical Information System within
Osaka City University Hospital between January 1999
and February 2012. This study protocol was approved by
the ethics committee of Osaka City University (approval
number, 1700). In our study, all patients received a single
agent EGFR-TKI therapy. The frequency of each adverse
event was evaluated during the period in which the
patients received EGFR-TKI therapy. All living participants
provided written informed consent. Formalin-fixed and
paraffin-embedded tissues or blood samples (when tissues
were not available) were collected. If the patients were
dead, formalin-fixed and paraffin-embedded tissues were
collected with the permission of the ethics committee.
Adverse events were assessed according to the National
Cancer Institute Common Terminology Criteria for Ad-
verse Events (version 3.0). We defined liver dysfunction as
one or more events of increased levels of aspartate amino-
transferase (AST), alanine aminotransferase (ALT), or
blood bilirubin. The frequency and severity of 3 major
non-hematological toxicities, including rash, diarrhea, and
liver dysfunction, were evaluated.
Genotyping methods
Genomic DNA was extracted from peripheral blood or
formalin-fixed and paraffin-embedded (FFPE) tissues using
a QIAGEN QIAampW DNA Blood Mini Kit (QIAGEN K.
K., Tokyo, Japan) and a QIAGEN QIAampW DNA FFPE
Tissue Kit (QIAGEN K.K.), according to the manufac-
turer’s instructions. Extracted DNA samples were stored at
−80°C before use. The DNA concentration was determined
by measuring the optical density at 260 nm (Nano DropW
ND-1000, Thermo Fisher Scientific, Inc., Wilmington, DE,
USA). In order to determine the CYP2D6 polymorphisms,
4 SNPs of the CYP2D6 gene, including rs1065852
(100C>T), rs5030865 (1758 G>A), rs16947 (2850C>T),
and rs1135840 (4180 G>C), were measured by real-time
PCR in order to evaluate the 5 mutated alleles: CYP2D6*1,CYP2D6*2, CYP2D6*10, CYP2D6*14A, and CYP2D-
6*14B. Genotyping was performed using TaqmanW Drug
Metabolism Genotyping AssaysTM (Applied Biosystems
Japan Ltd., Tokyo, Japan), according to the manufacturer’s
instructions. The following reagents were used for amplifi-
cation in a 10 μL reaction volume: 4.5 μL of DNA (around
50 ng), 0.5 μL of each CYP2D6 primer and probe mixture
(20×), and 5 μL of GTXexpressTM Master Mix. The thermal
cycling conditions consisted of an initial 20 seconds at 95°C,
followed by 40 cycles at 95°C for 15 seconds and at 60°C for
1 minute. Primers and probes were supplied by Applied
Biosystems, Japan, Ltd as Drug Metabolism Genotyping
AssaysTM. The assay IDs were C__11484460_40 for rs10-
65852, C_30634117D_30 for rs5030865, C__27102425_10
for rs16947, and C__27102414_10 for rs1135840. All
assays were performed in 96-well plates. Plates were read
on an Applied Biosystems 7500 Real-time PCR system
using the Sequence Detection System Software (Applied
Biosystems Japan Ltd.).
CYP2D6 phenotype
The metabolic functions of CYP2D6 are generally categor-
ized into 4 groups: ultra-rapid metabolizer (UM), exten-
sive metabolizer (EM), intermediate metabolizer (IM), and
poor metabolizer (PM) [16]. UM and EM result in normal
or better function, and IM and PM result in reduced func-
tions. CYP2D6 alleles were assigned based on the deter-
mination of the appropriate key mutations. CYP2D6*1
and CYP2D6*2 have normal activities, CYP2D6*10 and
CYP2D6*14B have impaired activities, and CYP2D6*5 and
CYP2D6*14A have no activities [17-20]. Alleles containing
additional copies of functional CYP2D6 genes were cate-
gorized as UM. The EM included a combination of 1 or 2
functional alleles, such as CYP2D6*1 or CYP2D6*2, the
IM phenotype included 2 impaired alleles, and the PM
phenotype included two non-functional alleles. In this
study, the CYP2D6 phenotype was categorized into 2
groups according to the metabolic levels: functional (UM
and EM) or reduced groups (IM and PM). Unknown phe-
notypes with a combination of impaired and undeter-
mined alleles, or 2 undetermined alleles, were excluded.
Statistical analysis
Comparisons of the characteristics between patients
treated with gefitinib or erlotinib were performed using
Fisher’s exact tests. Hardy-Weinberg equilibrium was
tested for with a goodness-of-fit χ2-test with 2 degree of
freedom to compare the observed genotype frequencies
among the subjects with the expected genotype frequen-
cies. In order to identify the risk factors for the adverse
events, gender, age, CYP2D6 activity, and stage were
selected and estimated for their potential confounding
effects on rash, diarrhea, and liver dysfunction by multi-
variate analysis. Unconditional logistic regressions were
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confidence intervals (CIs). All analyses were two-sided,
and p values of less than 0.05 were considered statisti-
cally significant. The statistical analyses were performed
with JMP 9 software (SAS Institute, Inc., Cary, NC,
USA) and software R version 2.10.0 (The R Foundation
for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
The study profile is illustrated in Figure 1. A total of 256
patients with advanced NSCLC who were treated with
gefitinib, and a total of 94 patients with advanced NSCLC
who were treated with erlotinib, were enrolled in the
study. DNA samples were collected from 289 patients, in-
cluding 232 patients who received gefitinib and 86 patients
who received erlotinib. Among them, 29 patients who
were treated with gefitinib were also treated with erlotinib
at different times. DNA samples were not obtained from
24 patients who were treated with gefitinib and 8 patients
who were treated with erlotinib because of screen failure.
Genomic DNA was extracted from 232 samples, including
16 blood samples and 216 tissues, in the gefitinib group,
and from 86 samples, including 15 blood samples and 71
tissues, in the erlotinib group.
The distributions of the patient characteristics among the
study subjects are summarized in Table 1. Comparisons of
the gefitinib and erlotinib groups that were representative
of the cohort indicated that the gefitinib group had a higher
rate of EGFR mutation-positive patients (gefitinib group,
95.6%; erlotinib group, 70.6%; *p < 0.001), and a higher rate
of poor performance status (≥2) patients (gefitinib group,
25.4%; erlotinib group, 8.2%; *p = 0.001). There were no
significant differences between the gefitinib and erlotinibGefitinib (n = 256)
Screen failure
(n = 24)
Gefitinib (n = 232)
FFPE tissue (n = 216)







Figure 1 Study profile. Diagram shows patient disposition in the gefitinibgroups in terms of age, sex ratio, histology, smoking status,
stages, CYP2D6 functions, infection with the hepatitis B or
C virus, or pretreatment liver function tests.
Comparison of the adverse events of gefitinib and erlotinib
Figure 2 shows the frequencies and severities of rash, diar-
rhea, and liver dysfunction. In the gefitinib treatment group,
the rates of rash of all grades and of grade 2 or greater were
66.8% and 19.8%, those of diarrhea were 25.9% and 9.1%,
and those of liver dysfunction were 48.3% and 25.0%,
respectively. In the erlotinib treatment group, the rates of
rash of all grades and of grade 2 or greater were 83.7% and
46.5%, those of diarrhea were 43.0% and 16.3%, and those
of liver dysfunction were 33.7% and 17.4%, respectively. The
patients treated with gefitinib had a significantly higher fre-
quency of liver dysfunction than the patients treated with
erlotinib (*p = 0.02). In contrast, the patients treated with
erlotinib had a significantly higher frequency of rash and
diarrhea than did the patients treated with gefitinib (*p =
0.003 and 0.04, respectively). Sixteen pneumonitis patients
were observed only in the gefitinib group, and pneumonitis-
related death was observed in 7 patients.
CYP2D6 alleles, genotype, and phenotype
The genomic DNA from a total of 289 patients was ana-
lyzed (Table 2). The distributions of CYP2D6 alleles were as
follows: CYP2D6*1, 236 alleles (40.8%); CYP2D6*2, 63 alleles
(10.9%); CYP2D6*10, 211 alleles (36.5%); CYP2D6*14A, 1
allele (0.2%); and undetermined, 67 alleles (11.6%). In a total
of 201 patients, genotyping predicted the normal function
of CYP2D6*1/*1 in 67 patients, CYP2D6*1/*2 in 22
patients, CYP2D6*1/*10 in 72 patients, CYP2D6*1/*14A in
1 patient, CYP2D6*1/undetermined allele in 7 patients,
CYP2D6*2/*2 in 9 patients, CYP2D6*2/*10 in 20 patients,Erlotinib (n = 94)
Screen failure
(n = 8)
Erlotinib (n = 86)
FFPE tissue (n = 71)







and erlotinib treatment groups.
Table 1 Patient characteristics in the gefitinib and erlotinib groups
Characteristics Gefitinib (n = 232) Erlotinib (n = 86) p value
Median age (Range) 67 (24–90) 66 (34–90) 0.36
< 70 139 57






Squamous cell carcinoma 8 5
Other 1 1
Smoking status 0.38
Ever smoker 130 43
Never smoker 102 43
ECOG performance status 0.001
0 30 11
1 143 68
≥ 2 59 7






















*Fisher’s exact test were applied to compare patient characteristics.
ECOG, Eastern Cooperative Oncology Group; EGFR, Epidermal Growth Factor Receptor; HCV, hepatitis C virus; HBs, hepatitis B surface; LFT, liver function test;
CYP2D6, cytochrome P450 2D6.


















































Figure 2 Comparison of adverse events between the gefitinib and erlotinib groups. The graphs show the proportion of adverse events in
all grade (A), and in grade ≥ 2 (B). In all grade, the patients treated with gefitinib had a significantly higher frequency of liver dysfunction than
did patients treated with erlotinib (*p = 0.003). In grade ≥ 2, liver dysfunction occurred significantly more often in the gefitinib group than in the
erlotinib group (*p = 0.04).
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total of 58 patients, genotyping predicted reduced func-
tion associated with CYP2D6*10/*10. In a total of 30
patients, the genotypes was unknown with results of




















CYP2D6*10/ undetermined 3 (1.0%)
undetermined/ undetermined 27 (9.3%)
Total 30 (10.3%)
CYP2D6, cytochrome P450 2D6.undermined alleles in 27 patients. The frequencies of
CYP2D6*1, CYP2D6*2, and CYP2D6*10 were compared
to the data previously reported in Japanese [21-23].
Compared to the Kubota’s, Nishida’s, and Tateishi’s
reports, the genotype distributions of each phenotype
among the patients were in Hardy-Weinberg equilib-
rium (*p = 0.69, 0.92, and 0.63, respectively).
Comparison of adverse events among CYP2D6 phenotypes
Figure 3 shows forest plots of the odds ratio for risk fac-
tors determined by multiple logistic regression models.
Each adverse event was divided into 2 groups: grade 0, 1
or grade ≥ 2. In the gefitinib cohort, the genotypes of 156
patients predicted normal function, and the genotypes of
50 patients predicted reduced function. Reduced func-
tion was associated with an increased risk of rash (rash:
OR, 0.44; 95% CI, 0.21–094; *p = 0.03). Reduced func-
tion was not associated with an increased risk of diar-
rhea or liver dysfunction (diarrhea: OR, 0.49; 95% CI,
0.17–1.51; *p = 0.20, liver dysfunction: OR, 1.08, 95%
CI, 0.52–2.34; *p = 0.84).
In the erlotinib cohort, the genotypes of 64 patients pre-
dicted normal function, and the genotypes of 16 patients
predicted reduced function. There were no associations
between any adverse events and CYP2D6 phenotypes
(rash: OR, 1.77; 95% CI, 0.54–6.41; *p = 0.35, diarrhea:
OR, 1.08; 95% CI, 0.21–7.43; *p = 0.93, liver dysfunction:
OR, 0.93; 95% CI, 0.20–5.07; *p = 0.93).
Discussion
We have demonstrated that reduced function of CYP2D6
in the gefitinib cohort was associated with an increased risk
of rash of grade 2 or more. No associations were observed
0.01 0.1 1 10







1.77 (0.54 - 6.41)
1.08 (0.21 - 7.43)
0.93 (0.20 - 5.07)
Odds Ratio (95% CI)
0.44 (0.21 - 0.94)
0.49 (0.17 - 1.51)





Figure 3 The odds ratio of each adverse event in EGFR-TKIs. The graphs show the forest plots for gefitinib (A), and for erlotinib (B). In the
gefitinib cohort, reduced function was associated with an increased risk of rash (*p = 0.03). In the erlotinib cohort, there were no associations
between any adverse events and CYP2D6 phenotypes.
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CYP2D6 phenotypes.
Almost all patients received appropriate supportive care
in their treatment. In our study, gefitinib treatment showed
different characteristics to erlotinib treatment. In a previ-
ous report without patient selection, treatment with gefiti-
nib was not associated with a significant improvement in
survival compared to placebo therapy [4,5]. However, erlo-
tinib has been shown to prolong survival in unselected and
EGFR wild-type patients with NSCLC after first-line or
second-line chemotherapy [6,24]. For these reasons, gefiti-
nib is administered to EGFR mutation-positive patients
and patients with a higher rate of poor performance status
(≥2).
In our study, gefitinib treatment showed different ad-
verse events to erlotinib treatment. Compared to the
side effects of erlotinib, patients treated with gefitinib
had a significantly higher frequency of liver dysfunction.
In the gefitinib group, the rate of liver dysfunction of all
grades in our study was 45.3%, including 19.0% of grade
1, 10.5% of grade 2, 14.7% of grade 3, and 1.1% of grade
4. In the erlotinib group, the rate of liver dysfunction in
our study was 21.3%, including 8.2% of grade 1, 8.2% of
grade 2, 4.9% of grade 3, and 0% of grade 4. With re-
spect to gefitinib therapy, Maemondo et al. reported a
rate of 55% of all grades of increased levels of amino-
transferases, and the rate of grade 3 or 4 was 21.5% in a
Japanese cohort [2]. Mitsudomi et al. reported a rate of
70.1% of all grades and a rate of 16.1% of grade 3 or 4
[25]. With respect to erlotinib therapy, an Asian phase
III study showed a rate of 37% for all grades of increased
levels of ALT, and a rate of 4% of grade 3 or 4 [26]. Our
results were similar to those found in previous gefitinib
and erlotinib phase III clinical trials in Asian subjects.Liver dysfunctions induced by gefitinib were reported
in a few cases in which hepatotoxicity caused by gefitinib
declined when gefitinib was changed to erlotinib. First,
Kijima et al. suggested the possibility that CYP2D6 poly-
morphisms were related to gefitinib-induced hepatotox-
icity. Their study described 3 cases with gefitinib-related
hepatotoxicity whose genotypes were CYP2D6*1/*10,
CYP2D6*10/*10, and CYP2D6*1/*5, with phenotypes of
EM, IM and EM, respectively. Second, Takeda et al.
reported a case and suggested that liver dysfunction was
attributable to a gefitinib allergy on the basis of a posi-
tive drug lymphocyte stimulation test (DLST) [27]. In
our study, the reduced function of CYP2D6 was not
associated with an increased risk of liver dysfunction in
the gefitinib cohort. Further analysis of the different
metabolic profiles of CYP enzymes should be performed
to clarify the metabolisms of gefitinib. The DLST of gefi-
tinib may be considered of value in some patients with
gefitinib-induced liver dysfunction.
The in vitro metabolism of gefitinib was investigated
using human liver microsomes, and gefitinib metabo-
lized mainly by expressed CYP3A4 produced a similar
range of metabolites as liver microsomes [15]. When
CYP3A4 function was low or inhibited by other drugs
that inhibit CYP3A4, gefitinib metabolism that involves
the formation of O-desmethyl-gefitinib and is deter-
mined by the CYP2D6 enzyme expressed in the liver
was increased marginally [15]. Therefore, the CYP2D6
enzyme is important for the metabolism of gefitinib not
only in patients with reduced CYP2D6 function, but
also in patients with normal CYP2D6 function who
take other drugs related to CYP3A4 inhibition. These
patients treated with gefitinib may have severe skin
rash due to decreased metabolism of gefitinib.
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CYP2D6*10, CYP2D6*14A and CYP2D6*14B, in 289
patients. The frequency of each allele was similar to those
reported in previous Japanese studies. Two reports showed
that the frequencies of the CYP2D6*1, CYP2D6*2,
CYP2D6*5, CYP2D6*10, and CYP2D6*14 alleles were
40.1%, 12.9%, 6.2%, 38.6%, and 2.2%, respectively, in 162
Japanese [21], and 43%, 12.3%, 4.5%, 38.1%, and 0.7%, re-
spectively, in 412 Japanese [22]. A further report showed
that the frequencies of the CYP2D6*1, CYP2D6*2,
CYP2D6*5, and CYP2D6*10 alleles were 42.3%, 9.2%, 6.1%,
and 40.8%, respectively, in 98 healthy Japanese [23]. Taken
together, the average frequencies of the functional and
reduced function alleles in these studies were 54.2%, and
44.7%, respectively. Asians have a high frequency of the
reduced function alleles that ranges from 43% to 47% [21-
23,28]. However, in Caucasians, the functional and reduced
function alleles represented a median frequency of 71%
and 26%, respectively, in all cohort studies [16] and 68.8%
and 25.36%, respectively, in German subjects [29]. Thus,
Asians have a higher frequency of reduced function al-
leles than do Caucasians. In addition, population-related
pharmacogenomics revealed a significant difference be-
tween Japanese and US patients in genomic distribution
and genotype-related associations with patient outcomes
for CYP3A4*1B and ERCC2 [30]. These facts may explain
the frequency differences of adverse events, particularly
rash, that are based on race.
CYP2D6 metabolizes many clinically important
drugs, including antidepressants, neuroleptics, beta-
blockers, anti-arrhythmics, and anti-cancer agents. In
breast cancer patients who were treated with tamoxi-
fen, the CYP2D6 phenotype was associated with sur-
vival [31] and the concentration of the active tamoxifen
metabolite, endoxifen [32]. Recently, in 2 single-agent
studies with gefitinib in bronchioloalveolar and head
and neck carcinomas, an association between the
occurrence of skin toxicity and survival was found
[33,34]. In our study, the subjects with reduced
CYP2D6 function were associated with an increased
risk of rash in the gefitinib cohort. Reduced CYP2D6
function may relate to longer overall survival as well as
poor metabolism of gefitinib. A prospective large clin-
ical trial is warranted to clarify these relationships.
Our findings had some limitations. The number of
patients was too small to have sufficient power to de-
tect significant differences in other adverse events
between CYP2D6 phenotypes. This study was a retro-
spective analysis. The identification of adverse effects
was prompted by monthly visits with hematological
tests or a medical interview for onset of symptoms, al-
though the hematological toxicities were in some cases
diminished at the time of next visit because of self-
judgment for discontinuation. The adverse events weregenerally controlled, except for interstitial lung disease.
The relation between CYP2D6 and carcinogenic risk
was not evaluated. The blood concentrations of gefiti-
nib and erlotinib and the metabolites of gefitinib and
erlotinib, were not measured. However, in clinical set-
tings, it may be difficult to perform blood sampling at
sufficient frequency to calculate area under the curve
(AUC). We could not separate the UM cohort from the
EM cohort. UM consists of CYP2D6*1 or CYP2D6*2,
and this group was included with EM in this study.
Other cytochrome P450 enzymes were not measured.
The relationship between these concentrations and
these enzyme phenotypes remain to be elucidated. Our
study may provide useful information regarding drug
selection for EGFR-TKIs. When gefitinib is adminis-
tered in combination with drugs which inhibit
CYP2D6 function, the frequency of severe rash by gefi-
tinib may be increased. When the patients with un-
known CYP2D6 phenotype, have a severe rash by
gefitinib, the change of gefitinib to erlotinib may be
sometimes useful, because the patient may have
reduced CYP2D6 function and CYP2D6 is not affected
the erlotinib metabolism. CYP2D6 genotyping and an
understanding of CYP2D6 function may be helpful in
predicting rash during gefitinib therapy.
Conclusions
We conclude that patients with reduced CYP2D6 activ-
ity treated with gefitinib had a significantly higher fre-
quency of rash than did patients with functional
CYP2D6. CYP2D6 phenotypes are a risk factor for the
development of rash in gefitinib therapy. In contrast, no
associations were found between the toxicity of liver
dysfunction and CYP2D6 activity in patients treated with
gefitinib. In our knowledge, our study is the first report
that CYP2D6 phenotypes are related to severity of rash
by gefitinib. Further clinical studies that include pro-
spective investigations in a large patient population with
pharmacokinetics/pharmacodynamics analyses, and that
include detailed information regarding CYP2D6 geno-
type, phenotype and activity, should be conducted.
Competing interests
The authors have made no disclosures.
Authors’ contributions
TS and TK conceived of the study, participated in the design of the study,
acquisition of data, performed the statistical analysis, drafted and revising the
manuscript. SK conceived of the study, participated in the design of the
study, acquisition of data and revising the manuscript. KU, MN, MK, HT, SM,
NY, NT were involved in acquisition of data. YK carried out real-time PCR
methods. KH participated in the design of the study, acquisition of data and
revising the manuscript. All authors have read and approved the final version
of the manuscript.
Acknowledgements
This research was partially supported by a Grant-in-Aid for Young Scientists
(B), the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Suzumura et al. BMC Cancer 2012, 12:568 Page 8 of 9
http://www.biomedcentral.com/1471-2407/12/568Author details
1Department of Respiratory Medicine, Graduate School of Medicine, Osaka
City University, Osaka, Japan. 2Department of Central Laboratory, Graduate
School of Medicine, Osaka City University, Osaka, Japan.
Received: 25 August 2012 Accepted: 28 November 2012
Published: 4 December 2012References
1. Kim E, Hirsh V, Mok T, Socinski M, Gervais R, Wu Y, Li L, Watkins C, Sellers M,
Lowe E, et al: Gefitinib versus docetaxel in previously treated non-small-
cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008,
372(9652):1809–1818.
2. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H,
Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or
chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl
J Med 2010, 362(25):2380–2388.
3. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K,
Shinkai T, Negoro S, Imamura F, Eguchi K, et al: Phase III study, V-15-32, of
gefitinib versus docetaxel in previously treated Japanese patients with
non-small-cell lung cancer. J Clin Oncol 2008, 26(26):4244–4252.
4. Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Sunpaweravong P,
Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in
pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947–957.
5. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J,
Thongprasert S, Tan E, Pemberton K, Archer V, et al: Gefitinib plus best
supportive care in previously treated patients with refractory advanced
non-small-cell lung cancer: results from a randomised, placebo-
controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Lancet 2005, 366(9496):1527–1537.
6. Shepherd F, Rodrigues Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S,
Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al: Erlotinib in
previously treated non-small-cell lung cancer. N Engl J Med 2005,
353(2):123–132.
7. Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, Yonei T,
Fujiwara K, Maeda T, Aoe K, et al: Comparison of the incidence and
pattern of interstitial lung disease during erlotinib and gefitinib
treatment in Japanese Patients with non-small cell lung cancer: the
Okayama Lung Cancer Study Group experience. J Thorac Oncol 2010,
5(2):179–184.
8. Lee JH, Jo YR, Park HS, Ryu YJ, Chun EM, Chang JH: Comparison of
gefitinib and erlotinib for Korean patients with advanced non-small cell
lung cancer. J Thorac Oncol 2009, 4(9):S692.
9. Togashi Y, Masago K, Fujita S, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y,
Kim YH, Mio T, Mishima M: Differences in adverse events between
250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients
with non-small cell lung cancer. Lung Cancer 2011, 74(1):98–102.
10. Uhm JE, Sun JM, Lee SH, Kong JH, Yun JA, Lee SM, Lee J, Park YH, Ahn JS,
Park K, et al: Comparison of erlotinib (Tarceva (TM)) versus gefitinib
(Iressa (R)) as the second line therapy for the treatment of advanced
non-small cell lung cancer patients: a randomized phase II trial. J Thorac
Oncol 2009, 4(9):S292.
11. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C,
Eckhardt SG, Tolcher A, Britten CD, Denis L, et al: Phase I and
pharmacologic study of OSI-774, an epidermal growth factor receptor
tyrosine kinase inhibitor, in patients with advanced solid malignancies.
J Clin Oncol 2001, 19(13):3267–3279.
12. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB,
Gianni L, Harris A, Bjork T, et al: Phase I safety, pharmacokinetic, and
pharmacodynamic trial of ZD1839, a selective oral epidermal growth
factor receptor tyrosine kinase inhibitor, in patients with five selected
solid tumor types. J Clin Oncol 2002, 20(21):4292–4302.
13. Kijima T, Shimizu T, Nonen S, Furukawa M, Otani Y, Minami T, Takahashi R,
Hirata H, Nagatomo I, Takeda Y, et al: Safe and successful treatment with
erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism
as a possible mechanism. J Clin Oncol 2011, 29(19):E588–E590.
14. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of
gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer
Res 2007, 13(12):3731–3737.15. McKillop D, McCormick A, Millar A, Miles G, Phillips P, Hutchison M:
Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005,
35(1):39–50.
16. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians,
Africans and their descendants. Pharmacogenomics 2002, 3(2):229–243.
17. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA: Deletion of the
entire cytochrome P450 CYP2D6 gene as a cause of impaired drug
metabolism in poor metabolizers of the debrisoquine/sparteine
polymorphism. Am J Hum Genet 1991, 48(5):943–950.
18. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-
Sundberg M: Inherited amplification of an active gene in the cytochrome
P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Proc Natl Acad Sci U S A 1993, 90(24):11825–11829.
19. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ: The human
debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification
of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
Am J Hum Genet 1989, 45(6):889–904.
20. Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M, Hiratsuka M:
Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10,
14A-B, 18, 27, 36, 39, 47–51, 53–55, and 57). Drug Metab Dispos 2008,
36(12):2460–2467.
21. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K: Frequencies of CYP2D6
mutant alleles in a normal Japanese population and metabolic activity
of dextromethorphan O-demethylation in different CYP2D6 genotypes.
Br J Clin Pharmacol 2000, 50(1):31–34.
22. Nishida Y, Fukuda T, Yamamoto I, Azuma J: CYP2D6 genotypes in a
Japanese population: low frequencies of CYP2D6 gene duplication but
high frequency of CYP2D6*10. Pharmacogenetics 2000, 10(6):567–570.
23. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S:
Analysis of the CYP2D6 gene in relation to dextromethorphan
O-demethylation capacity in a Japanese population. Clin Pharmacol Ther
1999, 65(5):570–575.
24. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T,
Marrano P, Whitehead M, Squire JA, et al: Role of KRAS and EGFR as
biomarkers of response to erlotinib in National Cancer Institute of Canada
Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26(26):4268–4275.
25. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T,
Satouchi M, Tada H, Hirashima T, et al: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): an
open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121–128.
26. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S,
Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for
patients with advanced EGFR mutation-positive non-small-cell lung
cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised,
phase 3 study. Lancet Oncol 2011, 12(8):735–742.
27. Takeda M, Okamoto I, Fukuoka M, Nakagawa K: Successful Treatment With
Erlotinib After Gefitinib-Related Severe Hepatotoxicity. J Clin Oncol 2010,
28(17):E273–E274.
28. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-
Sundberg M: Genetic analysis of the Chinese cytochrome P4502D locus:
characterization of variant CYP2D6 genes present in subjects with
diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994,
46(3):452–459.
29. Sachse C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in
a Caucasian population: allele frequencies and phenotypic
consequences. Am J Hum Genet 1997, 60(2):284–295.
30. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M,
Teramukai S, Ohe Y, Kubota K, Williamson SK, et al: Japanese-US common-
arm analysis of paclitaxel plus carboplatin in advanced non-small-cell
lung cancer: a model for assessing population-related
pharmacogenomics. J Clin Oncol 2009, 27(21):3540–3546.
31. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C,
Luccarini C, Shah M, Ingle S, Greenberg D, et al: CYP2D6 gene variants:
association with breast cancer specific survival in a cohort of breast
cancer patients from the United Kingdom treated with adjuvant
tamoxifen. Breast Cancer Res 2010, 12(4):R64.
32. Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG,
Olajide OA, Graham ML, Canale ST, et al: Genotype-guided tamoxifen dosing
Suzumura et al. BMC Cancer 2012, 12:568 Page 9 of 9
http://www.biomedcentral.com/1471-2407/12/568increases active metabolite exposure in women with reduced CYP2D6
metabolism: a multicenter study. J Clin Oncol 2011, 29(24):3232–3239.
33. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM,
Pierce C, Dekker A, Vokes EE: Phase II trial of gefitinib 250 mg daily in
patients with recurrent and/or metastatic squamous cell carcinoma of
the head and neck. Clin Cancer Res 2005, 11(23):8418–8424.
34. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K,
Crowley JJ, Gandara DR: Gefitinib therapy in advanced bronchioloalveolar
carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006,
24(12):1807–1813.
doi:10.1186/1471-2407-12-568
Cite this article as: Suzumura et al.: Reduced CYP2D6 function is
associated with gefitinib-induced rash in patients with non-small cell
lung cancer. BMC Cancer 2012 12:568.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
